Physician profile
Abdul Waheed
NPI 1851375042
$701.81
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2021: $22.88 · 2023: $77.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $77.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $77.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $163.51 | 2019 | |
| Allergan, INC. | $132.87 | 2019 | |
| Pulmonx Corporation | $116.17 | 2019 | |
| Organogenesis INC. | $77.59 | 2023 | Puraply |
| Astrazeneca Pharmaceuticals LP | $32.18 | 2019 | |
| Genentech USA, INC. | $26.81 | 2019 | |
| Electromed, INC. | $22.88 | 2021 | |
| Mylan Specialty L.P. | $17.57 | 2019 | |
| Grifols USA, LLC | $17.23 | 2019 | |
| Advanced Respiratory, INC | $15.16 | 2019 | |
| Resmed Corp | $15.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.69 | 2019 | |
| Shire North American Group INC | $14.47 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $12.81 | 2019 | |
| Glaxosmithkline, LLC. | $11.69 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Waheed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.